Ocular Hypertension

A 60-year-old man presented to the New England Eye Center as a same-day walk-in to the glaucoma clinic to establish care after having relocated to the Boston area.

Glaukos is moving forward with an FDA new drug application phase 3 clinical program for the iDose TR after finishing patient enrollment and randomization, according to a press release.

Alcon has signed an agreement to receive U.S. commercialization rights to Simbrinza from Novartis, according to a press release.

Betaliq has enrolled the first patient in a phase 2 trial investigating BTQ-1901 and BTQ-1902 for the treatment of glaucoma or ocular hypertension, according to a press release.

Roclanda has received marketing authorization from the Medicines and Healthcare Products Regulatory Agency in Great Britain, according to a press release from Aerie Pharmaceuticals.

Santen, Massachusetts Eye and Ear and Ulster University have formed a research initiative to investigate and develop novel therapies for the treatment of glaucoma, according to a press release.

MediPrint Ophthalmic announced that the SIGHT-1 clinical trial found a favorable safety and tolerability profile and demonstrated single dose efficacy of the LLT-BMT1 drug-eluting contact lens to treat mild to moderate glaucoma or ocular hypertension.

Teva Pharmaceuticals USA has launched the first generic version of Azopt in the United States.

Patients treated with Vyzulta for open-angle glaucoma and ocular hypertension had significantly better outcomes compared with most beta-blockers, according to results of a systemic review and network meta-analysis.

The Ministry of Food and Drug Safety in South Korea has granted regulatory approval for Vyzulta, according to a press release from Bausch Health.